Glycaemic outcomes in adults with type 2 diabetes over 34 weeks with the Omnipod® 5 Automated Insulin Delivery System
Authors' conclusion
These longer-term findings of Omnipod 5 AID System use demonstrate the potential value of AID in helping people with type 2 diabetes reach glycaemic targets.
Study context
- Population
- Adults with T2D and baseline HbA1c ≥ 8% (≥ 64 mmol/mol); non-insulin anti-hyperglycaemic medications permitted
- Participants
- 22 adults
- Comparison
- Omnipod 5 Automated Insulin Delivery (AID) vs standard therapy
- Outcome
- Primary safety endpoints: % time with sensor glucose ≥ 250 mg/dL and < 54 mg/dL
- Follow-up
- Through extension phase
Methodological detailsmulticentre, outpatient, 26-week extension phase
- Multicentre
- Outpatient
- 26-week extension phase
Main finding
As reported in the abstract
% time ≥ 250 mg/dL · extension phase
P = 0.0002 vs. standard therapy
Further findings
% time sensor glucose ≥250 mg/dL during the initial 8-week study
- Decrease in % time ≥250 mg/dL, from → to
- 27.4% ± 21.0% to 10.5% ± 8.8%
- P
- P < 0.0001
HbA1c change, standard therapy through extension
- HbA1c decrease
- 1.6% ± 1.2% (15.5 ± 13.1 mmol/mol)
- P
- P < 0.0001
Time in range (TIR) (70-180 mg/dL) change, standard therapy through extension
- TIR increase
- 22.4% ± 19.2%
- P
- P < 0.0001
BMI and total daily insulin · through extension
- No significant change in BMI and no observed increase in total daily insulin requirements
Safety
| Outcome | Standard therapy | P value |
|---|---|---|
| % time < 54 mg/dL · standard therapy through extensionOmnipod 5 AID vs Standard therapy · remained low | median 0.00% (IQR 0.00%–0.06%) | P > 0.05 |
- % time < 54 mg/dL: Omnipod 5 AID median 0.02% (IQR 0.00%–0.05%)
Original publication
Glycaemic outcomes in adults with type 2 diabetes over 34 weeks with the Omnipod® 5 Automated Insulin Delivery System. Diabetes Obes Metab. Published 9 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →